Reimbursement Review Reports


( Last Updated : February 3, 2023)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Sort descending Date Recommendation Issued
TBC filgrastim Cancelled
Admelog Insulin lispro Cancelled
Erbitux Cetuximab Cancelled
Zolinza vorinostat Cutaneous T-cell lymphoma CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Xofluza baloxavir marboxil Influenza CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
Nucala mepolizumab Eosinophilic granulomatosis with polyangiitis CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Emgality galcanezumab Episodic cluster headache CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Firazyr icatibant CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Talzenna talazoparib Breast cancer CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Xeljanz tofacitinib Cancelled